清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non–Small Cell Lung Cancer: An Emulated Target Trial

SABR波动模型 医学 放射治疗 肺癌 绝对风险降低 混淆 外科 随机对照试验 离格 癌症 死亡率 外科切除术 相对风险 放射外科 倾向得分匹配 癌症登记处 临床试验
作者
Eva Kagenaar,David Gibran Lugo-Palacios,Ajay Aggarwal,Andrew Hutchings,Stephen O’Neill,Bernard Rachet,John G. Edwards,Corinne Faivre-Finn,Richard Grieve
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:: JCO2600399-JCO2600399
标识
DOI:10.1200/jco-26-00399
摘要

Purpose Stereotactic ablative radiotherapy (SABR) is standard of care for inoperable early-stage non–small cell lung cancer (NSCLC), but there is little evidence to support SABR as an alternative to surgical resection. Randomized controlled trials (RCTs) have failed to recruit, and ongoing RCTs apply strict inclusion criteria. To our knowledge, this is the first emulated target trial comparing the effectiveness of SABR versus surgery in individuals with early-stage NSCLC eligible for either treatment. Methods We used England's National Cancer Registry data to identify individuals diagnosed with T1-2N0M0 NSCLC during 2015-2020, age 18-79 years with Zubrod performance status 0-2, or age 80+ years with performance status 0-1, who underwent SABR or surgical resection within 6 months of diagnosis. Treatment receipt was identified via linkage to Hospital Episode Statistics and the National Radiotherapy Data Set. The primary outcome was 3-year all-cause mortality; secondary outcomes included lung cancer–specific mortality and recurrence. An instrumental variable analysis reduced the risk of confounding by indication. Results A total of 12,546 met the eligibility criteria (2,299 SABR; 10,247 surgery). After adjustment, 3-year all-cause mortality estimates were 30.3% (SABR) and 21.6% (surgery; mean absolute risk difference 8.8 percentage points [pp], [95% CI, 1.4 to 16.2]; P = .02). Lung cancer–specific mortality estimates were 20.6% (SABR) and 14.5% (surgery; mean absolute risk difference 6.1 pp [95% CI, –0.6 to 12.9]; P = .07). The adjusted mean absolute risk difference in 3-year all-cause mortality for those age 80+ years was 4.3 pp ([95% CI, –3.7 to 12.3]; P = .62). Conclusion This emulated target trial found higher 3-year all-cause mortality after SABR versus surgery in early-stage NSCLC suitable for either modality, supporting that surgical resection should remain the preferred option. The findings support SABR as a curative-intent alternative, particularly for older people.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
junzzz完成签到 ,获得积分10
1秒前
2秒前
见物思理完成签到 ,获得积分10
7秒前
如懿完成签到,获得积分10
7秒前
如意亦瑶完成签到,获得积分10
9秒前
10秒前
18秒前
拼搏幻柏完成签到,获得积分10
19秒前
YNILY完成签到 ,获得积分10
24秒前
26秒前
岳晓燕完成签到 ,获得积分10
29秒前
35秒前
39秒前
luoqin完成签到 ,获得积分10
42秒前
43秒前
怼怼完成签到 ,获得积分10
43秒前
46秒前
机智的妙芹完成签到,获得积分10
48秒前
54秒前
58秒前
1分钟前
1分钟前
zxdzaz完成签到 ,获得积分10
1分钟前
成就小蜜蜂完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
夕阳下仰望完成签到 ,获得积分10
1分钟前
1分钟前
典雅涵瑶发布了新的文献求助10
1分钟前
稳重的秋天完成签到,获得积分10
1分钟前
1分钟前
留胡子的翠容完成签到,获得积分10
1分钟前
1分钟前
典雅涵瑶完成签到,获得积分10
1分钟前
1分钟前
ww完成签到,获得积分10
1分钟前
1分钟前
nanjing01完成签到 ,获得积分10
1分钟前
打打的应助被seeyou14采纳,获得20
1分钟前
善良士晋完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185496
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834498
捐赠科研通 7783092
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481346